The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
The miR-106b∼25 cluster, relatively high expressed in the early postnatal myocardium that still retains regenerative potential, directs networks of cell cycle regulators and stimulates proliferation of at least a subset of cardiomyocytes in animal models. In adulthood, the relative low cardiac expression of miR-106b∼25 sustains derepression of prohypertrophic cardiomyocyte gene programs that facilitate adverse remodeling in response to overload. Exploiting this endogenous regulator between cardiomyocyte hyperplasia and hypertrophy by viral gene delivery enhances the endogenous regenerative capacity of the mammalian myocardium and may provide a new therapeutic avenue for the treatment of ischemic heart failure.
To access the full paper, you can use this hyperlink .
Fri, 07 May
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
